Amgen, Daiichi in Exclusive Biosimilars Deal

Amgen and Daiichi Sankyo Co. have entered an exclusive agreement to commercialize nine biosimilars in Japan, including several biosimilars in late-stage development, and biosimilars of adalimumab (Humira), bevacizumab (Avastin) and trastuzumab (Herceptin).
 
Amgen will be responsible for the development and manufacturing of the biosimilars and Daiichi will file for marketing approval and will be responsible for distribution and commercialization in Japan, while Amgen has limited rights to co-promote the products. Amgen will retain all additional distribution and commercialization rights for the biosimilar programs outside of Japan. Financial terms were not disclosed.
 
“Amgen is excited to collaborate with Daiichi Sankyo as we seek to drive adoption and build confidence in biosimilars as a means of enhancing patient access to more affordable therapeutic options worldwide,” said Scott Foraker, vice president and general manager of Biosimilars at Amgen.